8 weeks · 0 milestones
Conduct a real case analysis of a specific named biotechnology application: a named CRISPR therapy in clinical trials (using a named IND in the ClinicalTrials.gov registry), a specific named synthetic biology product with regulatory status, or a named agricultural biotech product with a published safety assessment. The analysis must address three dimensions: (1) scientific validity — what does the evidence actually show about efficacy and mechanism? (2) regulatory status — what approvals exist, what is still pending, and what evidence gaps remain? (3) ethical implications — what are the genuine contested trade-offs, using a named ethical framework applied explicitly? Public clinical trial registries, regulatory agency filings (FDA, EMA), and peer-reviewed literature provide the evidence base, all publicly accessible. Reviewed by a biotechnology researcher, bioethicist, or industry practitioner who challenges whether the evidence you cited is sufficient to support your conclusions about efficacy — requiring you to evaluate evidence quality, not just summarise published claims.